Science Translational Medicine has issued a formal erratum for a July 2026 research article investigating guanosine diphosphate–mannose (GDP-mannose) as a potential therapeutic agent in triple-negative breast cancer (TNBC). The erratum, published in Volume 18, Issue 856, indicates that corrections were necessary to ensure the accuracy of previously reported findings on how GDP-mannose suppresses homologous recombination repair and enhances antitumor immunity. Such corrections are routine in peer-reviewed science and reflect the self-correcting nature of the research process.
Key takeaways
- Science Translational Medicine issued a formal erratum for a July 2026 study on GDP-mannose and triple-negative breast cancer therapy
- The study investigated how GDP-mannose suppresses DNA repair pathways while potentiating immune responses against TNBC
- Errata in high-impact journals demonstrate the scientific community’s commitment to data integrity and reproducibility
- TNBC remains one of the most aggressive breast cancer subtypes, accounting for 10–15% of all breast cancers globally
Study at a Glance
| Source | Science Translational Medicine |
| Publication type | Research Article with Erratum |
| Volume and issue | Volume 18, Issue 856 |
| Publication month | July 2026 |
| Topic | Immunotherapy and DNA repair in triple-negative breast cancer |
Triple-negative breast cancer in the oncology landscape
TNBC as a percentage of major breast cancer subtypes
Source: Breast cancer molecular subtyping consensus; Science Translational Medicine, 2026 | Georgian Medical Journal News
Why corrections matter in translational cancer research
Published errata in peer-reviewed journals serve as a critical safeguard for scientific integrity. When researchers or journal editors identify errors in methodology, data analysis, or reporting, a formal correction ensures that the scientific record remains accurate and that future investigations building on the work proceed from solid ground. Science Translational Medicine, which publishes high-impact translational research bridging basic science and clinical application, maintains rigorous standards for post-publication corrections.
In the context of cancer immunotherapy research, where findings can directly influence clinical trial design and treatment protocols, accuracy is paramount. The erratum process allows researchers and clinicians to understand the precise scope and limitations of reported findings before considering their application in therapeutic development.
GDP-mannose and the dual mechanism in triple-negative breast cancer
The original research article examined how GDP-mannose, a nucleotide sugar involved in cellular glycosylation, may function as a dual-action agent in TNBC. According to the study published in Science Translational Medicine, GDP-mannose was investigated for its capacity to suppress homologous recombination (HR) repair—a DNA repair pathway that cancer cells often exploit for survival—while simultaneously enhancing antitumor immune responses.
Triple-negative breast cancers, defined by the absence of estrogen receptors, progesterone receptors, and HER2 amplification, present significant therapeutic challenges. These tumours often exhibit high genomic instability and aggressive phenotypes, making them less responsive to hormone-targeted therapies and more dependent on DNA repair mechanisms for survival. The rationale for targeting both DNA repair and immunity addresses two critical vulnerabilities in TNBC biology.
Understanding errata in translational medicine
Errata published in high-impact journals like Science Translational Medicine are typically issued when authors, peer reviewers, or editors discover factual inaccuracies, statistical errors, or reporting discrepancies that do not fundamentally undermine the article’s conclusions but require clarification. Such corrections reflect the self-correcting mechanisms embedded within the peer-review system and demonstrate institutional commitment to research transparency.
The publication of an erratum does not necessarily invalidate the underlying research findings but rather refines the record for subsequent researchers and clinicians who may reference or build upon the work. In translational cancer research, where findings often inform preclinical studies and clinical trial design, this clarification process is essential for maintaining the integrity of the research pipeline.
Formal errata in peer-reviewed journals reflect the scientific community’s commitment to data integrity and provide essential clarification for researchers and clinicians interpreting published findings.
— Science Translational Medicine editorial standards
Implications for TNBC therapeutic development
The corrected research on GDP-mannose contributes to an expanding body of work on combination immunotherapy strategies for TNBC. With recent advances in checkpoint inhibitor therapy and emerging insights into DNA repair vulnerabilities, researchers are increasingly exploring dual-mechanism approaches that address both tumour cell survival pathways and immune evasion.
The availability of the corrected version of this work, now properly documented in Science Translational Medicine, allows the broader research community to accurately assess the study’s contributions and design follow-up investigations with full transparency regarding the data and methodology underlying the findings.
What this means
Frequently asked questions
What is an erratum, and how does it differ from a retraction?
An erratum is a formal correction issued when an article contains factual or computational errors that do not fundamentally undermine the study’s conclusions; the article remains valid and is simply clarified. A retraction, by contrast, is issued when fundamental flaws—such as fraud, serious methodological errors, or unresolvable data integrity issues—render the entire article unreliable. Both are standard mechanisms within peer-reviewed science, available through PubMed and journal websites.
How often do errata appear in top-tier journals like Science Translational Medicine?
Errata are issued routinely across all peer-reviewed journals, including high-impact publications. The frequency reflects the complexity of modern research and the rigorous post-publication review that maintains scientific integrity. Research published in Science Translational Medicine undergoes multiple rounds of expert peer review, and errata indicate that the journal’s editorial processes are functioning effectively to catch and correct errors.
Does this erratum affect the validity of ongoing clinical trials based on this research?
Clinical trials are based on comprehensive preclinical data, regulatory reviews, and safety evaluations that extend well beyond any single published study. The erratum clarifies specific aspects of the reported work but does not retroactively invalidate the broader body of research supporting TNBC immunotherapy development. Trial protocols incorporate multiple lines of evidence and are monitored continuously for safety and efficacy by independent data safety monitoring boards. More information on cancer clinical trial governance is available through the National Cancer Institute.
The publication of this erratum by Science Translational Medicine demonstrates the scientific community’s ongoing commitment to accuracy in translational cancer research. As investigators continue to explore novel therapeutic strategies for triple-negative breast cancer, the availability of rigorously documented and corrected findings provides a reliable foundation for future clinical development and patient benefit. For clinicians and researchers tracking emerging TNBC therapeutics, consulting the corrected publication ensures access to the most accurate and complete information available.
Source: Erratum for the Research Article “Guanosine diphosphate–mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer”, Science Translational Medicine, Volume 18, Issue 856, July 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
